The concentration of the amniotic fluid angiogenin and interleukin-6 in the pregnancy with elevated maternal serum human chorionic gonadotropin during the second trimester

Won, Hye Sung; Yoo, Hye Kyung; Kim, So Ra; Jung, Ji Yoon; Jung, Bok Kyung; Lee, Pil Ryang; Lee, In Sik; Kim, Ahm

Abstract

OBJECTIVE
This study is to measure the level of concentration of angiogenin, a cause of potent neovascularization and a marker of ischemia, and of interleukin-6 (IL-6), an indicator of acute inflammation, in the amniotic fluid of patients with elevated maternal serum free beta-hCG level during the second-trimester.
MATERIALS AND METHODS
Twenty patients with elevated maternal serum free beta-hCG level (>2.5 MoM) at double screening test of Down syndrome were compared with the controlled group (<2.0 MoM). This study includes singleton gestation, gestational age of 14-18 weeks, and has no evidence of fetal structural and chromosomal anomalies. The levels of amniotic angiogenin and IL-6 were measured by enzyme-linked immunosorbent assay (ELISA) method. Data were analyzed by Mann-Whitney U test. p value <0.05 was considered significant.
RESULTS
Amniotic angiogenin levels in the studied group were much lower than those in the controlled group (p<0.05), whereas the difference of IL-6 levels between the two groups was not significant. Nine studied patients delivered small for gestational age infants, but only one controlled patient (p<0.05) had the same infant. Other variables of perinatal outcome were not different between the two groups.
CONCLUSION
That amniotic fluid angiogenin levels are significantly lower in patients with elevated maternal serum free beta-hCG suggests an inadequate angiogenesis. Elevated maternal serum free beta-hCG levels correlate with fetal growth restriction. IL-6 values in both groups have no significant difference.